R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids
Figure 7
Quantitative analysis of microglia marker proteins in the dorsal horn of the spinal cord.
a Western Blot analysis of Iba-1 immunoreactivity in the ipsi lateral L4/5 mouse spinal cord dorsal horn 7 days after SNI and treatment with R-flurbiprofen (4.5 mg/kg twice daily) or vehicle. Representative blot of n = 4 per group. B. The densitometric ratio of Iba-1 versus loading control β-actin was used for statistics; P<0.05. b Quantitative EIA analysis of phopho-p38 MAP kinase in the L4/5 mouse spinal cord dorsal horn ipsilateral to 7 days SNI or CCI and treatment with R-or S-flurbiprofen (4.5 mg/kg twice daily), dexamethasone (positive control) or vehicle. c Respective representative Western Blot of phospho-p38 and p38 alpha. d Immunofluorescence and e Western Blot analysis of microglia CD68 immunoreactivity in the spinal cord dorsal horn 7 days after nerve injury and treatment with R-flurbiprofen (4.5 mg/kg twice daily) or vehicle ipsi lateral to the nerve lesion (n = 3 per group). f, g CD11b immunofluorescence of dorsal horn microglia and densitometric CD11b image analysis in the ipsilateral dorsal horn 21d after SNI. Scale bar: 100 µm.